Research

Bruce Psaty, headshot

Dr. Bruce Psaty, professor, received a four-year R01 from the National Heart, Lung and Blood Institute (NHLBI) for $6 million for the project “Plasma proteomics in CHS and population biology.” The grant will support SomaLogic aptamer-based protein assays in about 3000 participants in the Cardiovascular Health Study. Key personnel from DoM include James Floyd and Rozenn Lemaitre.


Ellen Schur, headshot

Dr. Ellen Schur, associate professor, received a K24 from NHLBI for $592,000 over five years for her project “Fostering patient-oriented research in cardiometabolic disease pathogenesis and prevention.” The grant will provide advanced training for researchers to study heart disease. Dr. Psaty will serve as an advisory board member.


Judith Tsui, headshot

Dr. Judith Tsui, associate professor, received an R34 from the National Institute on Drug Abuse for $643,770 over three years for her project “Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs.”

The purpose of the research is to develop and pilot a community-pharmacy based model of care for persons who inject drugs to improve access to testing and treatment for HCV, in addition to other potentially life-saving medications.


Luke Wander, headshot

Dr. Pandora "Luke" Wander, assistant professor, received an R03 from National Institute of Diabetes and Digestive and Kidney Diseases for $194,000 for her two-year project “Circulating miRNA Signatures of Beta-Cell Response to Metformin or Insulin in Youth with Dysglycemia.” The goal is to help prevent pediatric type 2 diabetes or induce prediabetes remission.


David Watkins, headshot

Dr. David Watkins, associate professor, received a UW Royalty Research Fund grant for $40,000 for his 1-year project “Bridging the gap between evidence and policy: An analysis of opportunities for action on rheumatic heart disease in Uganda.” This project aims to address the questions: What does it take to bring a new rheumatic heart disease (RHD) initiative to scale in the context of an overloaded health system? Where has scientific evidence failed to translate into policy change? And how might these implementation barriers be remediated? The analytic approach builds on existing activities underway as part of the American Heart Association-funded grant, “Building a Case to Invest in Rheumatic Heart Disease Prevention and Control in Limited Resource Settings,” which is already collecting a variety of quantitative and qualitative data on health system opportunities and constraints around RHD in Uganda, a country with high rates of RHD.